U.K. flagellation

UCB's Transformation

U.K. flagellation

While some national media are asking why British biotech companies can't seem to make it to the finish line, U.K. investors are more sanguine about how shareholders will benefit from last week's deal for Belgium's UCB Group to acquire Celltech Group plc. Nevertheless, the market watchers also can point out reasons for a continuing series of U.K. takeouts by foreign acquirers.

By one view, the proposed sale of Celltech (LSE:CCH; CLL, Slough,

Read the full 730 word article

How to gain access

Continue reading with a
two-week free trial.